<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02909192</url>
  </required_header>
  <id_info>
    <org_study_id>2016P001775</org_study_id>
    <nct_id>NCT02909192</nct_id>
  </id_info>
  <brief_title>Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease</brief_title>
  <official_title>Bright Light Modulation of Non-motor Symptoms in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      Disruption of sleep and alertness is one of the most disabling non-motor symptoms of&#xD;
      Parkinson's disease (PD). Mechanisms leading to impaired sleep and alertness in PD are not&#xD;
      well understood, and treatment options remain limited. The proposed research will examine&#xD;
      markers of the circadian system, sleepiness and sleep quality in PD patients. Further, the&#xD;
      project will examine effects of bright light exposure on circadin function, sleep and&#xD;
      alertness in PD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parkinson's Disease Sleep Scale (PDSS-2) score to measure sleep quality</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale (ESS) score to measure daytime sleepiness</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS) score to measure the severity and frequency of non-motor symptoms</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma melatonin levels collected through blood samples to measure melatonin amplitude and circadian regulation</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Bright light therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated twice daily with bright light therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dim-Red light therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated twice daily with dim-red light therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light Therapy Device</intervention_name>
    <arm_group_label>Bright light therapy</arm_group_label>
    <arm_group_label>Dim-Red light therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Diagnosis of idiopathic PD as defined by the United Kingdom PD Society Brain Bank&#xD;
             Criteria&#xD;
&#xD;
          2. PD Hoehn and Yahr stage 2-4&#xD;
&#xD;
          3. Pittsburgh Sleep Quality Index (PSQI) score ≥ 5&#xD;
&#xD;
          4. Treatment with levodopa and/or dopamine agonist; adjunctive PD medications will be&#xD;
             allowed&#xD;
&#xD;
          5. Stable dose of PD medications for at least 4 weeks prior to the study screening.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Atypical or secondary forms of parkinsonism&#xD;
&#xD;
          2. Co-existent significant sleep apnea (as assessed by polysomnography- derived&#xD;
             apnea/hypopnea index ≥15 events/hr of sleep)&#xD;
&#xD;
          3. Co-existent restless legs syndrome (RLS), as assessed by the International&#xD;
             Classification of Sleep Disorders (ICDS) diagnostic criteria for RLS&#xD;
&#xD;
          4. Cognitive impairment as determined by the Mini-Mental State Examination (MMSE) score&#xD;
             of ≤ 26&#xD;
&#xD;
          5. Presence of depression defined as the Beck Depression Inventory (BDI) score &gt;14&#xD;
&#xD;
          6. Untreated hallucinations or psychosis (drug-induced or spontaneous)&#xD;
&#xD;
          7. Use of hypno-sedative drugs for sleep or stimulants; participants will be allowed to&#xD;
             taper these drugs and will become eligible 4 weeks after the taper is completed&#xD;
&#xD;
          8. Use of Selective Serotonin Reuptake Inhibitors (SSRIs) / Serotonin-Norepinephrine&#xD;
             Reuptake Inhibitors (SNRIs) antidepressants, unless the participant has been on a&#xD;
             stable dose for at least 3 months prior to the screening&#xD;
&#xD;
          9. Use of medications known to affect melatonin secretion, such as lithium, alpha- and&#xD;
             beta-adrenergic antagonists&#xD;
&#xD;
         10. Shift work, currently or within the prior 3 months&#xD;
&#xD;
         11. Travel through ≥ 2 time zones within 60 days prior to study screening&#xD;
&#xD;
         12. Hematocrit &lt;32 mm3&#xD;
&#xD;
         13. Pre-existing glaucoma/retinal disease contraindicated for light therapy (LT)&#xD;
&#xD;
         14. Dense cataracts&#xD;
&#xD;
         15. Use of medications known to photosensitize retinal tissue (phenothiazines,&#xD;
             chloroquine, amiodarone, St. John's Wort)&#xD;
&#xD;
         16. Unstable/serious medical illness.&#xD;
&#xD;
         17. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandar Videnovic, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aleksandar Videnovic, MD, MSc</last_name>
    <phone>617-724-3837</phone>
    <email>avidenovic@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Stauder, B.S.</last_name>
      <phone>617-726-9589</phone>
      <email>mstauder@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Aleksandar Videnovic, MD</investigator_full_name>
    <investigator_title>Assistant Neurologist</investigator_title>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Excessive Daytime Sleepiness</keyword>
  <keyword>Circadian Rhythms</keyword>
  <keyword>Light Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

